4 CONTRAINDICATIONS

This effect was not seen in idiopathic

14. Clinical Studies

Phosphodiesterase-5 (PDE-5) inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat.Known hypersensitivity to sildenafil or any component of the tablet. Hypersensitivity, including anaphylactic reaction, anaphylactic shock and anaphylactoid reaction, has been reported in association with the use of sildenafil. Sildenafil tablets are contraindicated in patients with: Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see Warnings and Precautions (5.1)] . Phosphodiesterase-5 (PDE-5) inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat. Known hypersensitivity to sildenafil or any component of the tablet. PAH (sildenafil citrate 3%, placebo 2%) patients.

The incidence of epistaxis was also higher in sildenafil citrate-treated

4.3 Concomitant Guanylate Cyclase (GC) Stimulators

Vasodilation effects may be more common in patients with hypotension or on antihypertensive therapy. Use in pulmonary veno-occlusive disease (PVOD) may cause pulmonary edema and is not recommended. Hearing or visual impairment: Seek medical attention if sudden decrease or loss of vision or hearing occurs. Pulmonary hypertension (PH) secondary to sickle cell disease: Sildenafil citrate may cause serious vaso-occlusive crises. Use with strong CYP3A inhibitors: Not recommended.

6.2 Postmarketing Experience

Concomitant PDE-5 inhibitors: Avoid use with Viagra ®or other PDE-5 inhibitors. Pediatric use information is approved for Viatris Specialty LLC’s, REVATIO (sildenafil) tablets. However, due to Viatris Specialty LLC’s marketing exclusivity rights, this drug product is not labeled with that information. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Table of Contents FULL PRESCRIBING INFORMATION: CONTENTS*1 INDICATIONS AND USAGE2 DOSAGE AND ADMINISTRATION2.1 Recommended Dosage in Adults3 DOSAGE FORMS AND STRENGTHS4 CONTRAINDICATIONS5 WARNINGS AND PRECAUTIONS5.1 Hypotension5.2 Worsening Pulmonary Vascular Occlusive Disease5.3 Epistaxis5.4 Visual Loss5.5 Hearing Loss5.6 Combination with other PDE-5 Inhibitors5.7 Priapism5.8 Vaso-occlusive Crisis in Patients with Pulmonary Hypertension Secondary to Sickle Cell Disease6 ADVERSE REACTIONS6.1 Clinical Trials Experience6.2 Post-marketing Experience7 DRUG INTERACTIONS8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy8.2 Lactation8.4 Pediatric Use8.5 Geriatric Use8.6 Patients with Hepatic Impairment8.7 Patients with Renal Impairment10 OVERDOSAGE11 DESCRIPTION12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action12.2 Pharmacodynamics12.3 Pharmacokinetics13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility14 CLINICAL STUDIES17 PATIENT COUNSELING INFORMATION*Sections or subsections omitted from the full prescribing information are not listed.

Indications and Usage for Sildenafil Oral Suspension

1 INDICATIONS AND USAGE AdultsSildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [see Clinical Studies (14)] .Pediatric use information is approved for Viatris Specialty LLC’s, REVATIO (sildenafil) tablets. Sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [see Clinical Studies (14)] . 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage in AdultsOral DosageThe recommended dosage of sildenafil tablet is 20 mg three times a day [see Clinical Studies (14)] .Pediatric use information is approved for Viatris Specialty LLC’s, REVATIO (sildenafil) tablets. The recommended dosage of sildenafil tablet is 20 mg three times a day [see Clinical Studies (14)] . 4 CONTRAINDICATIONS Sildenafil tablets are contraindicated in patients with:Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see Warnings and Precautions (5.1)] .Concomitant use of riociguat, a guanylate cyclase stimulator. patients with a concomitant oral vitamin K antagonist (9% versus

• Common side effects include headaches and facial flushing.
• Less common effects may include nasal congestion or upset stomach.
• Do not use sildenafil if allergic to it or similar drugs.
• Pregnant women should consult a healthcare provider before use.
• Be aware of the signs of allergic reactions.
• Sildenafil may also be indicated for certain heart conditions.
• Emergency services should be contacted if adverse reactions occur.
• Keep a record of any side effects experienced.

2% in those not treated with concomitant vitamin K antagonist).The

safety of sildenafil citrate is

2.5 Dosage Adjustments in Special Populations

Archived from the original on 22 August 2009. Archived from the original on 25 June 2007. "Viagra from the pharmacist: insight from reclassification in New Zealand". Archived from the original on 17 May 2021. ^ "Generic Viagra developers queue up, but may have to wait".

Serious side effects

Archived from the original on 28 December 2021. ^ "Approved Viagra copies flood drugstores in Korea". ^ "Viagra prescriptions almost triple in a decade". Archived from the original on 1 July 2024. ^ "MHRA reclassifies Viagra Connect tablets to a Pharmacy medicine".

Risk Summary

^ "Viagra to be available without prescription in UK". If you can't find what you were looking for, please contact us using one of the methods below so we can better serve you. Due to the Coronavirus (COVID-19) outbreak worldwide, the global demand for some Personal Protective Equipment (PPE) is exceeding current supply availability. In addition, the manufacturing of the PPE and many other wound care/infection prevention products have been impacted by the global response to the Coronavirus. While you may see product availability reduction in the near-term, please be assured that we at McGuff Medical are continuing to work diligently to ensure an uninterrupted supply of products and alternative products to you. unknown in patients with bleeding disorders

2.1 Dosage Information

^ "Viagra patent tossed out by Supreme Court: Decision allows generic versions of drug to be produced". Archived from the original on 18 September 2013. ^ "Pfizer Canada drops Viagra price after generic versions get Supreme Court green light". Archived from the original on 30 November 2012. Archived from the original on 27 December 2013.

Drug Interactions

"In rare move, Pfizer asks Supreme Court to reconsider ruling that killed Viagra patent". Archived from the original on 5 February 2013. "The Supreme Court of Canada holds Pfizer's Viagra patent invalid". Archived from the original on 20 May 2013. ^ "Actavis Launches Generic Viagra in Europe as Patents Expire".

Preexisting medical conditions

Archived from the original on 29 October 2013. "What Will Happen When Viagra Goes Generic?". Archived from the original on 23 April 2011. ^ "Is Viagra about to lose its pulling power in the UK?". Archived from the original on 30 October 2013. or active peptic ulceration.5.4 Visual LossWhen used to treat erectile

Medical uses

Additionally, in order to ensure healthcare providers have access to the PPEs they need, the McGuff Company is temporarily limiting PPEs to healthcare providers. As always, please feel free to reach out to our McGuff Customer Service team with any questions that you may have. If you are a consumer or patient please visit this version. See full prescribing information for SILDENAFIL TABLETS.SILDENAFIL tablets, for oral useInitial U.S. Approval: 1998INDICATIONS AND USAGEAdultsSildenafil tablets are a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening.

Starting Sildenafil: Recommended First-Time Dosage

(1)DOSAGE AND ADMINISTRATIONAdults: 20 mg three times a day. (2.1)DOSAGE FORMS AND STRENGTHSTablets: 20 mg (3)CONTRAINDICATIONSWARNINGS AND PRECAUTIONSVasodilation effects may be more common in patients with hypotension or on antihypertensive therapy. (5.1)Use in pulmonary veno-occlusive disease (PVOD) may cause pulmonary edema and is not recommended. (5.2)Hearing or visual impairment: Seek medical attention if sudden decrease or loss of vision or hearing occurs. (5.4, 5.5)Pulmonary hypertension (PH) secondary to sickle cell disease: Sildenafil citrate may cause serious vaso-occlusive crises.

8.7 Patients with Renal Impairment

(5.8)ADVERSE REACTIONSDRUG INTERACTIONSUse with strong CYP3A inhibitors: Not recommended. ( 7, 12.3)Concomitant PDE-5 inhibitors: Avoid use with Viagra sildenafil 50 mg tab ®or other PDE-5 inhibitors. (5.6)Pediatric use information is approved for Viatris Specialty LLC’s, REVATIO (sildenafil) tablets. However, due to Viatris Specialty LLC’s marketing exclusivity rights, this drug product is not labeled with that information.See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.Revised: 3/2026 Sildenafil tablets are a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening. Adults: 20 mg three times a day. dysfunction, non-arteritic anterior ischemic optic

Publication types

5 WARNINGS AND PRECAUTIONS 5.1 HypotensionSildenafil citrate has vasodilatory properties, resulting in mild and transient decreases in blood pressure. Before prescribing sildenafil citrate, carefully consider whether patients with certain underlying conditions could be adversely affected by such vasodilatory effects (e.g., patients on antihypertensive therapy or with resting hypotension [blood pressure less than 90/50], fluid depletion, severe left ventricular outflow obstruction, or autonomic dysfunction). Monitor blood pressure when co-administering blood pressure lowering drugs with sildenafil citrate.5.2 Worsening Pulmonary Vascular Occlusive DiseasePulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of sildenafil citrate to patients with veno-occlusive disease, administration of sildenafil citrate to such patients is not recommended. Should signs of pulmonary edema occur when sildenafil citrate is administered, consider the possibility of associated PVOD.5.3 EpistaxisThe incidence of epistaxis was 13% in patients taking sildenafil citrate with PAH secondary to CTD. neuropathy (NAION), a cause of decreased

vision including permanent loss of vision, has been reported post-marketing in temporal association with the

• Sildenafil tablets are classified as phosphodiesterase inhibitors.
• They are quick-acting but effects vary by individual.
• Avoid taking with other erectile dysfunction medications.
• Liver or kidney impairment may require dose adjustments.
• Do not use sildenafil during sexual activity if unadvised.
• Safe sexual activity involves knowing your health status.
• Window for maximum effectiveness is around 1 hour before.
• Avoid excessive physical exertion after taking sildenafil.

use of PDE-5 inhibitors, including sildenafil.

• Sildenafil tablets 125 mg are used to treat erectile dysfunction.
• The medication enhances blood flow to the penis.
• It’s important to follow prescribed dosages for safety.
• Sildenafil can cause side effects like headache or dizziness.
• Do not take sildenafil if you’re on nitrate medications.
• Store tablets in a cool, dry place away from children.
• The effect typically lasts for about 4-6 hours.
• Consult your doctor before starting sildenafil treatment.